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Background: Activated hepatic stellate cells are the main source of excessive collagen deposition in liver fibrosis.
Here we report the inhibitory effects of the combinational treatment of two natural products, astragalus
polysaccharide (APS) and β-elemene (ELE) on the activation of human liver hepatic stellate cell line LX-2 cells.
Methods: Cultured LX-2 cells were treated with different concentrations of APS or ELE for 24 or 48 hours. Cell
viability/apoptosis was measured by MTT assay and Annexin V/PI staining , activation related genes including
α-SMA and CD44 expressions were measured by real-time PCR and western blot respectively.
Results: The majority of LX-2 cells showed morphological change in the presence of APS or ELE for 24 hours.
Treatment with APS + ELE for 24 or 48 hours significantly inhabited the cell proliferation compared with APS or ELE
treatment alone on LX-2 cells. APS + ELE may block the up-regulation of α-SMA and CD44 both in mRNA and
protein levels through TGF-β pathway in LX-2 cells.
Conclusion: APS or ELE treatment alone on LX-2 cells could inhibit cell proliferation and induce apoptosis. The
combinational treatment using APS + ELE significantly increased the killing efficiency on LX-2 cells. α-SMA and
CD44 expressions was inhibited upon APS + ELE treatment through TGF-β pathway in LX-2 cells. The results
indicated a novel treatment using natural products for liver diseases with anti-fibrotic effect.
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Liver fibrosis is characterized by the accumulation of
extracellular matrix proteins like collagen. It occurs in
many types of chronic liver diseases induced by viral in-
fection, alcohol intake and high-fat diet. Hepatic stellate
cells (HSCs) were identified as the main cell type that
produce collagen in liver fibrosis when these cells were
activated [1]. So, looking for drugs which can prevent
the activation or induce apoptosis of HSCs will be very
helpful for treating liver fibrosis.
LX-2 cell line is a well characterized human HSC cells
line, it is similar to that of “activated” HSC cells in vivo.* Correspondence: minghui_yang2008@126.com
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unless otherwise stated.LX-2 cells retain the key features of cytokine signaling,
retinoid metabolism, and fibrogenesis of activated HSCs
[2]. So, it is widely used for the studies of pathogenesis
of liver fibrosis and developing new approaches for liver
fibrosis treatment [3-6].
It was believed that liver fibrosis was irreversible previ-
ously, however, recent studies suggested that liver fibrosis
was reversible. Several mechanisms were involved in the
process:1. Kupffer cells (KC) derived cytokines can pro-
mote HSC activation in the development of liver fibrosis,
however, TNF-related apoptosis-inducing ligand (TRAIL)
expressed by KCs can induce apoptosis of HSCs in fibrosis
resolution [7]. 2. Nature killer (NK) cells may directly kill
activated HSCs and promote liver fibrosis resolution [8].
Recent studies indicated that astragalus polysaccharide
(APS) and β-elemene (ELE) showed prominent anti-
fibrotic effect in treating liver fibrosis [9-12]. The role ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Effects of APS on the viability of LX-2 cells. LX-2 cells
were treated with different concentration of APS as indicated for 24
or 48 hours. Viability was determined by MTT assay. **P < 0.01,
***P < 0.001 compared to untreated cells at the same time point.
Figure 2 Effects of ELE on the viability of LX-2 cells. LX-2 cells
were treated with different concentration of ELE as indicated for 24
or 48 hours. Viability was determined by MTT assay *P < 0.05,
**P < 0.01, ***P < 0.001 compared to untreated cells at the same
time point.
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gholicus, in immune regulation has been well studied.
Specifically, APS may regulate the KC cell function and
promote the cytotoxicity of NK cells [13,14]. These results
suggest that APS may be helpful in the resolution of liver
fibrosis by regulating the function of immune cells in the
liver. ELE is a volatile terpene found in many plants such
as celery and mint. ELE has been widely used in treating
liver fibrosis and liver cancer in China [15]. It can strongly
inhibit the production of extracellular matrix (ECM) by
activated HSCs. So, we believe that the combination of
ELE and APS may not only block the production of ECM
but also promote the resolution of liver fibrosis by regulat-
ing the function of immune cells in the liver which will be
an ideal treatment for liver fibrosis. In this study, we
employed the LX-2 cell line to investigate the anti-fibrotic




APS was obtained from Cinorch Pharmaceutical (Tianjin,
China). ELE was obtained from Sigma .Human HSC LX-2
cell line was obtained from The Fourth Military Medical
University. Dulbecco’s modified Eagle’s medium (DMEM),
penicillin/streptomycin and glutamine were purchased
from Gibco (Foster City, CA, USA), fetal bovine serum
(FBS) was purchased from Sijiqing (Hangzhou, China).
TGF-β1 was purchased from Peprotech (Rocky Hill, NJ,
USA).
Cell culture
LX-2 cells were cultured in DMEM supplemented with
10% FBS, 100 IU/ml penicillin/streptomycin and 1%
glutamine. Cultures were incubated at 37 degree in a
humidified atmosphere of 5% CO2, and the medium was
changed every day.
Measurement of cell viability
Cell viability was determined by MTT assay. A total of
1X104 cells were seeded in 96 well plates, When the
confluence reached to 80% ~ 90%, medium was changed,
different concentrations of APS, ELE or combination of
APS and ELE (APS + ELE) were added into the medium.
24 or 48 hours later, 20 μl 5 mg/ml MTT was added into
wells and incubated for 4 hours. After adding 150 μl
DMSO, the optical density was measured at 490 nm.
Annexin V/PI assays for apoptosis
Per manufacturer’s protocol (ebioscience, San Diego, CA,
USA),cells were stained with Annexin V–FITC and PI,
and evaluated for apoptosis by flow cytometry. Briefly, 1 X
106 cells were washed twice with phosphate-buffered sa-
line (PBS), and stained with 5 μl of Annexin V–FITC and10 μl of PI (5 μg/ml) in 1X binding buffer (10 mM HEPES,
pH 7.4, 140 mM NaOH, 2.5 mM CaCl2) for 15 min at
room temperature in the dark. The apoptotic cells were
determined using a BD FACSAria (Mansfield, MA, USA).
Both early apoptotic (Annexin V-positive, PI-negative),
late apoptotic (Annexin V-positive and PI-positive) and
dead (Annexin V-negative and PI-positive) cells were
included in cell death determinations.
Real-time quantitative PCR
Total RNA was isolated from cells using Trizol Reagent
(Invitrogen) and quantified. cDNA was synthesized from
1μg of RNA using High Capacity cDNA Reverse Tran-
scription Kit (Applied Biosystems, Foster City, CA, USA).
The cDNA was used as templates for realtime quantitative
Figure 3 Effects of APS combined with ELE on the viability of LX-2 cells, LX-2 cells were treated with different concentration of APS,
ELE or APS + ELE as indicated for 24 or 48 hours. Viability was determined by MTT assay **P < 0.01, compared to ELE treated cells in the
same time point, **P < 0.01, compared to APS treated cells at the same time point.
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SYBR Green PCR Master Mix (Applied Biosystems). The







LX-2 cells were lysed in RIPA buffer containing 1%
PMSF and protease inhibitor cocktail. The cell lysate
was centrifuged at 12000 rpm for 20 min at 4 degree
and the supernatant was collected. Protein concentration
was determined by using BCA protein assay. A total of
40 μg of cell lyse were separated by SDS-PAGE gel and
transferred to NC membranes. The membranes were in-
cubated with anti-CD44s and, anti-α-SMA antibodies
(Abcam, Cambridge, MA, USA), anti-β-actin antibody
(Santa Cruz, Dallas, TX, USA). After washing 3 timesFigure 4 Apoptosis of LX-2 cells analyzed by flow cytometry 24 hours af
C: APS:3mg/ml D: Combined.with TBS/T buffer, membranes were incubated with a
horseradish peroxidase-conjugated secondary antibodies
(Boster, Wuhan, China) for 1 h. The blots were devel-
oped with ECL (Pierce) according to the manufacturer’s
instruction.
Statistical analysis
Data was presented as mean ± standard deviation (S.D.) of
three independent experiments. The results were analyzed
by one-way analysis of variance (ANOVA) or Student
t test using SPSS17.0 software. Differences were consid-
ered as being significant at P < 0.05.
Results
The inhibitory effects of APS and ELE on LX-2 cells
In control group, LX-2 cells showed typical HSC morph-
ology with extended dendrites. 24 hours after APS treat-
ment, cell fusion was observed. In addition, some of the
cells showed a round cell shape with decreased dendrites
and increased vesicular structures. 48 hours later, most ofter treatment of APS, ELE or APS + ELE: A: Control; B: ELE:0.2mg/ml;
Figure 5 α-SMA and CD44 mRNA of LX-2 cells analyzed by Real-time PCR in Control group, TGF-β group, TGF-β + ELE + APS group
(*P < 0.01).
Figure 6 α-SMA and CD44 protein levels of LX-2 cells analyzed
by Western blot in Control group, TGF-β group, TGF-β + ELE +
APS group.
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vesicular structures. Enlarged round shape and increased
vesicular structures were also observed in ELE group at 48
hours after treatment. Similar morphology was be observed
as early as 24 hours after the combination of both APS and
ELE (APS + ELE) treatment.
The influence of APS and ELE on LX-2 cell proliferation by
MTT assay
Both APS and ELE could significantly inhibit the cell via-
bility of LX-2 cell in a dose- and time-dependent manner
as shown in Figures 1 and 2. We showed that when the
concentration of APS was higher than 3 mg/ml, the viabil-
ity of APS treated cells only slightly decreased when the
dose was further increased. So we selected 3 mg/ml in the
following experiments. Similarly, 0.2 mg/ml of ELE was
selected based on the dose response curve.
We further explored the effects on LX-2 cell viability of
combination treatment of both 3 mg/ml APS and 0.2 mg/
ml ELE. As shown in Figure 3, we found that the viability
determined by MTTassay was 7.6% ± 0.58% in APS + ELE
group 24 after treatment, which was significantly lower
than in APS alone treatment (10.8 ± 0.34%) or ELE alone
(10.6 ± 0.26%) (p < 0.01). 48 hours later, the viability de-
creased to 2.8% ± 0.16% in APS + ELE group compared
with 10.3 ± 0.45% in APS alone or in 3.4 ± 0.12% ELE
alone (p < 0.01).
The effects of APS, ELE alone or APS + ELE treatment on
LX-2 cell apoptosis by flow cytometry analysis
The externalization of phosphatidylserine (PS) in living
cells was the early events in apoptosis. Annexin V showed
a strong and specific affinity for PS and was used here to
detect early stage of apoptosis. Annexin V was used in
conjunction with propidium iodide (PI) for identification
of early and late apoptotic cells. Viable cells with intact
membranes exclude PI, whereas the membranes of dead
cells are permeable to PI. So, cells that are in early apop-
tosis were Annexin V positive and PI negative, cells thatwere in late apoptosis both Annexin V and PI positive and
already dead cells were PI single positive. Here, we used
Annexin V/PI staining to detect cell apoptosis 24 hour
after APS, ELE or APS + ELE treatment. As shown in
Figure 4, compared with control group, most cells were in
early or late stage of apoptosis with APS and ELE treat-
ment for 24 hours respectively. 24 hours treatment with
APS + ELE, the percentage of dead cells (PI single posi-
tive) was significantly higher than APS or ELE alone
group.Combination of APS and ELE blocked the TGF-β1 induced
up-regulation of α-SMA and CD44 in both mRNA and
protein levels in LX-2 cells
As shown in Figures 5 and 6, both mRNA and protein
levels of fibrogenic gene α-SMA and CD44 were signifi-
cantly increased in LX-2 cells in the presence of TGF-β1
as reported previously. Upon the APS + ELE treatment,
the expressions of α-SMA and CD44 induced by TGF-
β1 in LX-2 cells were significantly blocked in both
mRNA and protein levels (Figures 5 and 6).
Figure 7 The mechanism of the anti-fibrosis effect of APA and ELE.
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In current study, we demonstrated that single use of
APS or ELE inhibited the growth of LX-2 cells dose- and
time- dependently. Combination use of APS and ELE
showed significantly increased efficiency in growth in-
hibition compared with APS or ELE alone. Most of LX-2
cells were in late stage of apoptosis and some of LX-2
cells were already dead with treated with APS + ELE for
24 hours in Annexin V/PI staining. These data suggested
that APS can synergistically induce LX-2 cell apoptosis
together with ELE.
Recent studies showed that the proliferation and activa-
tion of HSCs played a key role in the development of liver
fibrosis [1,16]. Targeting the proliferation of HSCs can be
considered as novel therapeutic strategy for treating liver
fibrosis [17,18]. Drugs which can inhibit the proliferation
of HSC cell lines in vitro showed promising anti-fibrotic
studies effect in vivo [12,18,19]. In addition, the resolution
of liver fibrosis largely depended on the apoptosis of HSCs
[20,21]. Our results indicated that APS + ELE may not only
directly block that proliferation of HSC cell line LX-2 cells
but also induce LX-2 cells apoptosis, these data suggested
that the combinational use of APS and ELE may be also
effective in rodent liver fibrosis models or in humans.
The activation of HSCs was characterized by the trans-
formation of quiescent HSCs to extracellular matrix produ-
cing phenotype termed myofibroblast [1]. The activation
marker α-SMA, which was involved in HSC contraction,
was greatly increased in this process of HSC activation
[22]. CD44 belongs to transmembrane protein which can
bind to hyaluronic acid, fibronectin, laminin and collagen.
CD44 was critical in cell motility, tumor development and
invasion [23]. Recently, CD44 was reported to be involved
in the activation HSCs after liver damage [24]. CD44 was
expressed in neutrophils, epithelial cells and endothelial
cells and it played important roles in cell adhesion, hyalur-
onic acid degradation, angiogenesis and cytokine release
[25]. CD44 can bind to F-actin through its intracellularankyrin domain and participate the formation of pseudo-
podia and cell migration [26]. In the sinusoids, cell connec-
tion and signaling was mediated by cell adhesion
molecules, including selectin and CD44. The binding of
CD44 and its ligands was essential in regulating the adhe-
sion of tumor cell with platelets, leucocytes, sinusoidal
endothelial cells and stellate cells, therefore was considered
critical in liver metastases [27]. In liver cancer patients with
HBV infection and cirrhosis, more attention should be paid
at early stage on CD44v expression which was strongly as-
sociated with metastases [28]. In addition, it was reported
that fibroblast activation protein (FAP) might activate
HSCs and increase the expression of MMP2 and CD44
which can enhance the adhesion and invasion of HSCs
[29].
Conclusions
In summary, we used cultured human HSC cell line LX-
2 to study the growth inhibition effects of APS and ELE
by morphology study, MTT assay and Annexin V/PI
staining. We showed that both APS and ELE can inhibit
LX-2 cell growth and they may synergistically induce
LX-2 cell apoptosis (Figure 7). Furthermore, APS + ELE
treatment blocked HSC cell activation marker α-SMA
and CD44 expression in both mRNA and protein levels
of in LX-2 cells after TGF-β treatment. Our study pro-
vided a possible mechanism for the anti-fibrotic effect of
APS and ELE, thus a potential new treatment for liver
disease wit anti-fibrotic effect.
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